Development of highly potent active pharmaceutical ingredients (HPAPIs) can be quite challenging. Crossing the boundary from small molecules to biologics into antibody-drug conjugate (ADC) territory adds levels of complexity. This presentation provides a case study and an overview of best practices and infrastructure requirements that facilitate accelerated timelines to clinic, including advantages of seamless integration of operations for HPAPIs, monoclonal antibodies, and ADCs and process scaleup. To learn more, please see our presentation.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center